1. Academic Validation
  2. Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes

Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes

  • Toxicol Appl Pharmacol. 2012 Sep 15;263(3):296-302. doi: 10.1016/j.taap.2012.07.001.
Xue-Feng Wu 1 Xing-Xin Wu Wen-Jie Guo Qiong Luo Yan-Hong Gu Yan Shen Ren-Xiang Tan Yang Sun Qiang Xu
Affiliations

Affiliation

  • 1 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, China.
Abstract

In the present paper, we aimed to examine the novel effects of cerebroside D, a glycoceramide compound, on murine experimental colitis. Cerebroside D significantly reduced the weight loss, mortality rate and alleviated the macroscopic and microscopic appearances of colitis induced by dexran sulfate sodium. This compound also decreased the levels of TNF-α, IFN-γ and IL-1β in intestinal tissue of mice with experimental colitis in a concentration-dependent manner, accompanied with markedly increased serum level of IL-10. Cerebroside D inhibited proliferation and induced Apoptosis of T cells activated by concanavalin A or anti-CD3 plus anti-CD28 Antibodies. The compound did not show an effect on naive lymphocytes but prevented cells from entering S phase and G2/M phase during T cells activation. Moreover, the treatment of cerebroside D led to Apoptosis of activated T cells with the cleavage of Caspase 3, 9, 12 and PARP. These results showed multiple effects of cerebroside D against activated T cells for a novel approach to treatment of colonic inflammation.

Figures
Products